Goldman Sachs Reiterates Sell on Ionis Pharmaceuticals (IONS) Following CRL
Tweet Send to a Friend
Goldman Sachs analyst, Salveen Richter, reiterates a Sell rating and $36.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
